NCLs (neuronal ceroid lipofuscinoses), a group of inherited neurodegenerative lysosomal storage diseases that predominantly affect children, are the result of autosomal recessive mutations within one of the nine cln genes. The wild-type cln gene products are composed of membrane and soluble proteins that localize to the lysosome or the ER (endoplasmic reticulum). However, the destiny of the Cln variants has not been fully characterized. To explore a possible link between ER quality control and processing of Cln mutants, we investigated the fate of two NCL-related Cln6 mutants found in patient samples (Cln6 G123D and Cln6 M241T ) in neuronal-derived human cells. The point mutations are predicted to be in the putative transmembrane domains and most probably generate misfolded membrane proteins that are subjected to ER quality control. Consistent with this paradigm, both mutants underwent rapid proteasome-mediated degradation and complexed with components of the ER extraction apparatus, Derlin-1 and p97. In addition, knockdown of SEL1L [sel-1 suppressor of lin-12-like (Caenorhabditis elegans)], a member of an E3 ubiquitin ligase complex involved in ER protein extraction, rescued significant amounts of Cln6 G123D and Cln6
INTRODUCTION
NCLs (neuronal ceroid lipofuscinoses), also referred to as Batten disease, are the most common paediatric neurodegenerative diseases having an incidence rate of 1 in 12500 in the U.S. population [1] . Their significant clinical feature is progressive encephalopathy confined to macular cerebral degeneration [2] . The symptoms of NCL encephalopathy include epileptic seizures, dementia, progressive psychomotor decline, visual retrocession and blindness, and ultimately leads to premature death [3] . The histological hallmark of NCLs is the accumulation of proteolipid pigment deposits in the lysosomes of many cell types [4, 5] . Patients suffering from Batten disease show intracellular inclusions predominately in neurons caused by lysosomal accumulation of ceroid and lipofuscin with mitochondrial ATP synthase subunit C
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Most NCLs are inherited as autosomal recessive mutations within six identified and three unidentified genes, denoted cln1- 9 . Defective Cln proteins result in lysosomal dysfunction and accumulation of lysosomal storage material in the brain of affected children, leading to the development of several pathogenic processes and neurodegeneration. Current genetic classification of NCLs varies in clinical phenotypes from more benign to extremely severe, depending on the specific genetic defect of the encoded protein. They are divided into four main groups: infantile NCL, late infantile NCL, juvenile JNCL and adult NCL, and four other less frequent entities. The Cln polypeptides are both soluble and membrane proteins located in either endosomal/ lysosomal compartments (Cln1, palmitoyl-protein thioesterase; Cln2, tripeptidyl peptidase I; Cln3 and Cln5) or the ER (endoplasmic reticulum) (Cln6 and Cln8) [7] . Cln4, Cln7 and Cln9 proteins have not yet been identified. Interestingly, the processing and fate of aberrant Cln proteins is not clear. In fact, hereditary mutations within cellular genes can result in clinically significant pathologies, such as cystic fibrosis, hereditary emphysema [8] , nephrogenic diabetes insipidus [9] and oculocutaneous albinism [10] . Since ER quality control has been implicated in these diseases, it is likely that it plays a role in the processing of Cln variants and the development of NCL.
Mutations within the cln6 gene cause both the classical lateinfantile and juvenile forms of NCL [11] . The present study explores the role of ER quality control in the early processing events of ER-localized Cln6 mutant proteins [12] [13] [14] . Experiments revealed that Cln6 mutant proteins were degraded in a proteasomedependent manner. In addition, knockdown of SEL1L [sel-1 suppressor of lin-12-like (Caenorhabditis elegans)], a protein involved in the disposal of aberrant ER proteins, rescued the degradation of the Cln6 mutants. The results supports the theory that ER quality control may contribute to the onset of NCL type 6 and offers insight towards potential therapy against NCL.
EXPERIMENTAL

Cell lines and antibodies
Human U373-MG astrocytoma cells expressing Cln6 polypeptides (U373 Cln6wt , U373 Cln6G123D and U373 Cln6M241T cells) (where wt is wild-type) were generated and maintained as described previously [15] . Anti-PDI (protein disulfide-isomerase) [16] , anti-SEL1L [17] and anti-calnexin {AF8 [18] , a gift from Professor M. Brenner (Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, U.S.A.} antibodies were utilized as described previously. Anti-GAPDH (glyceraldehyde-3-phosphate dehydrogenase), anti-p97, anti-Derlin-1 and anti-BiP (immunoglobulin heavychain-binding protein) antibodies were purchased from Chemicon, Sigma and Stressgen respectively.
cDNA constructs
The Cln6 chimaeras were cloned from the Cln6 DNA template (A.T.C.C. Image ID 3878776) with an N-terminus HA (haemagglutinin) epitope tag (AYPYDVPDYA) into the retroviral vector pLpCX (Clontech). Cln6 G123D and Cln6 M241T mutant cDNAs were generated from PCR fragments by site-directed mutagenesis [15] .
Immunoprecipitation
Immunoprecipitations were performed as described previously [15] . Briefly, cells (10 6 ) were lysed in 0.5% NP-40 (Nonidet P40) lysis mix, followed by incubation with the respective antibody and protein A-agarose beads. The immunoprecipitates were resolved using SDS/PAGE (12.5% gels) and subjected to immunoblot analysis using the respective immunoglobulin.
Pulse-chase analysis
Pulse-chase experiments were performed as described previously [15] . Cells were labelled with [ 35 S]methionine and chased in non-radioactive methionine (25 mM). Cln6 proteins were recovered from NP-40 cell lysates using an anti-HA antibody and resolved using SDS/PAGE (12.5% gels). The polyacrylamide gel was dried, exposed to autoradiographic film and the polypeptides were quantified by densitometry analysis using an Alpha Imager 3400 densitometer. 
Immunofluorescence microscopy
RESULTS
Cln6 mutant molecules are stabilized by inclusion of proteasome inhibition
Cln6 is a 311 amino acid non-glycosylated ER membrane protein that is predicted to contain either five or six transmembrane domains [12, 14] . To investigate the processing of Cln6 mutants implicated in the development of NCL, an HA epitope tag was introduced at the N-terminus of Cln6 wt and Cln6 variants (Cln6
G123D
and Cln6 M241T ) with missense mutations in the predicted transmembrane domains [19] . These mutants were chosen for study because they were identified in NCL patients [12] [13] [14] . These polar residues within the membrane bilayer most probably cause the mutant to exist in a misfolded conformation, generating a potential target for the ER quality-control apparatus. HAepitope tagged versions of Cln6 wt , Cln6 G123D and Cln6
M241T
were transduced into U373 cells (U373 Cln6wt , U373 Cln6G123D and U373 Cln6M241T cells) and the stability of the Cln6 proteins was examined by pulse-chase analysis ( Figure 1A ). U373 Cln6wt , U373 Cln6G123D and U373 Cln6M241T cells were metabolically labelled for 15 min and chased for up to 45 min. Equivalent levels of Cln6 wt polypeptides were recovered throughout the chase period ( Figure 1A, lanes 1-4) , a result that is consistent with protein stability. In contrast, levels of Cln6 G123D polypeptides decreased rapidly during the chase period ( Figure 1A , lanes 5-8) with a half-life of ∼20 min ( Figure 1B) . Interestingly, the migration difference of Cln6 G123D compared with Cln6 wt or Cln6 M241T is probably due to a conformational change in the overall structure that is specific to the mutation. A similar result was observed in mutants of the multi-spanning membrane protein Sec61p and the soluble protein p97 [20, 21] . Even more striking was the instability of Cln6
M241T polypeptides ( Figure 2A , lanes 9-12). Only a minute amount of Cln6 M241T polypeptides were recovered from the 0 min chase period and even less from the 15 min chase point, suggesting a half-life of less than 15 min (Figure 2A, lane 10) . These results demonstrate that Cln6 mutants are degraded with fast kinetics.
To examine whether the Cln6 mutants are degraded by the proteasome, Cln6 protein levels were examined from U373 Cln6wt , U373 Cln6G123D and U373 Cln6M241T cells treated with or without
the proteasome inhibitor ZL 3 VS (carboxybenzyl-leucyl-leucylleucyl vinyl sulfone) (10 μM) for 5 h [22] . Cln6 proteins recovered from the respective cells were analysed using an immunoprecipitation and immunoblot method (Figure 2A ). U373 cells transduced with empty vector were used as a negative control (Figure 2A, lanes 9 and 11) . Equivalent levels of Cln6 wt were recovered independently of inhibitor treatment (Figure 2A , lanes 1, 2, 5 and 6), whereas a minimal number of polypeptides was recovered from U373 Cln6G123D and U373 Cln6M241T cells (Figure 2A,  lanes 3 and 7) . However, significant amounts of Cln6 G123D and Cln6
M241T polypeptides were recovered from ZL 3 VS-treated cells (Figure 2A, lanes 4 and 8) are extracted from the ER to the cytosol and degraded by the proteasome.
To further confirm that the instability of Cln6 G123D and Cln6
M241T polypeptides was due to their transport out of the ER, we examined the effect of eeyarestatin, an inhibitor of the dislocation reaction [23] . U373, U373 Cln6wt , U373 Cln6G123D and U373 Cln6M241T cells were treated with or without eeyarestatin (5 μg/ml) or the proteasome inhibitors lactacystin [24] (10 μM) or ZL 3 VS (5 μM) for 12 h. Total cell lysates were subjected to immunoblot analysis using an anti-HA antibody (Figure 2B ). An immunoblot performed using an anti-GAPDH antibody verified equal protein loading ( Figure 2B, lanes 20-38) . As expected, treatment with the proteasome inhibitors lactacystin and ZL 3 VS caused a significant increase in both Cln6 G123D and Cln6
M241T polypeptides ( Figure 2B , lanes 10, 12, 16 and 18 respectively). Moreover, eeyarestatin treatment caused increased levels of Cln6 G123D and Cln6 M241T polypeptides ( Figure 2B , lanes 4 and 6), albeit to a lower level than the proteasome inhibitors. This is probably due to the inability of eeyarestatin to completely attenuate dislocation of ER substrates [23] . Eeyarestatin treatment caused a greater accumulation of Cln6 G123D than Cln6 M241T , probably due to differences in their degradation kinetics (Figure 1B) . In summary, Cln6 G123D and Cln6 M241T polypeptides were stabilized upon inclusion of proteasome or dislocation inhibitors.
Stabilized Cln6 mutant proteins are localized to the ER
The localization of the stabilized Cln mutant Cln6 G123D was examined using fluorescence microscopy ( Figure 3) . U373 Cln6wt and U373 Cln6G123D cells treated with or without ZL 3 VS (2.5 μM) for 12 h were probed for Cln6 or PDI polypeptides using anti-HA (Figure 3 , panels 1-2 and 7-8) and anti-PDI (Figure 3 , panels 3-4 and 9-10) antibodies, respectively. The merged images represent the co-localized polypeptides (Figure 3 , panels 5-6 and Figure 3 Stabilized Cln6 mutants localize to the ER U373 Cln6wt (panels 1-6) and U373 Cln6G123D (panels 7-12) cells treated with (+) or without (−) the proteasome inhibitor ZL 3 VS were probed with anti-HA (panels 1, 2, 7 and 8) and anti-PDI (panels 3, 4, 9 and 10) antibodies and subjected to indirect immunofluorescence microscopy. The yellow regions in the Merge panels (panels 5, 6, 11 and 12) represent the co-localized material.
11-12). The intensity of the Cln6
wt fluorescence signal was independent of proteasome-inhibitor treatment (Figure 3 , panels 1-2) and co-localized with the ER resident protein PDI (Figure 3 , panels 5-6). In contrast, a significant increase in the fluorescence signal was observed in U373 Cln6G123D cells treated with proteasome inhibitor (Figure 3 , compare panels 7 and 8). The ER localization of Cln6 G123D polypeptides upon proteasome inhibition was confirmed by their co-localization with PDI (Figure 3, panel 12) . In addition, a subcellular fractionation experiment [25] 
Cln6
G123D and Cln6 M241T polypeptides interact with the dislocation complex
The dislocation of ER proteasomal substrates is mediated by the interaction with both ER and cytosolic proteins. Derlin-1, an ER membrane protein essential for the dislocation of certain ER degradation substrates, together with the cytosolic complex of AAA (ATPase associated with various cellular activities) p97-Ufd1-Npl4, facilitates the extraction of ER proteins out of the ER [26] . To further define the processing of the Cln6 G123D and Cln6
M241T mutant proteins, we examined whether Cln6
G123D
and Cln6 M241T form a complex with the specific components of the dislocation apparatus, Derlin-1 and p97. Derlin-1 was recovered from U373 Cln6wt , U373 Cln6G123D and U373 Cln6M241T cells treated with or without ZL 3 VS (10 μM) for 5 h using an antiDerlin-1 antibody. The immunoprecipitates and total cell lysates were subjected to immunoblotting using anti-HA ( Figure 4A,  lanes 1-14) and anti-Derlin-1 ( Figure 4A, lanes 15-28) antibodies. As expected, Derlin-1 polypeptides were recovered from all samples ( Figure 4A, lanes 15-28) . Consistent with previous results (Figure 2 ), Cln6 G123D and Cln6 M241T were stabilized in the presence of a proteasome inhibitor ( Figure 4A , lanes 11 and 13). Both Cln6 G123D and Cln6 M241T polypeptides were coprecipitated with Derlin-1 molecules from proteasome inhibitortreated U373 Cln6G123D and U373 Cln6M241T cells ( Figure 4A, lanes 4  and 6) . The lack of a polypeptide signal from U373 and U373 Cln6wt cells ( Figure 4A, lanes 1, 2 and 7) confirmed the specificity of the anti-Derlin-1 immunoprecipitation. These results suggest that Derlin-1 is probably involved in the dislocation of the Cln6 G123D and Cln6
M241T mutants. We next examined a possible interaction between Cln6 G123D and Cln6
M241T and p97 ( Figures 4B and 4C ). Cln6 polypeptides recovered from U373 Cln6wt , U373 Cln6G123D and U373 Cln6M241T cells treated with or without ZL 3 VS (5 μM) for 12 h were subjected to immunoblot analysis. As expected, significant amounts of Cln6 G123D and Cln6 M241T proteins were recovered from the proteasome inhibitor-treated cells ( Figures 4B and 4C, lane 9) . p97 exclusively co-precipitated with Cln6 G123D and Cln6 these results suggest that Derlin-1 and p97 probably mediate the extraction of Cln6 G123D and Cln6 M241T polypeptides from the ER into the cytosol.
Cln6
G123D and Cln6 M241T are dislocated in a SEL1L-dependent manner Ubiquitination of ER degradation substrates through a specific E3 ligase is a pre-requisite for the dislocation of most degradation substrates [27] . In fact, ER localized membrane proteins that complex with E3 ligases play an important role in the dislocation process. SEL1L, an ER membrane protein that complexes with the E3 ligase Hrd1 [HMG-CoA (3-hydroxy-3-methylglutaryl-CoA) reductase degradation protein 1], Derlin-1, Derlin-2 and p97 [28, 29] has been implicated in the dislocation of both membrane and soluble degradation substrates [17, 30] . Is SEL1L involved in the degradation of Cln6 G123D and Cln6 M241T ? To address this question, we examined the steady state levels of Cln6 polypeptides in cells that stably express shRNA (smallhairpin RNA) against SEL1L (shRNA-SEL1L) or GFP (green fluorescent protein) (shRNA-GFP) [17] . The shRNA-GFP cells were utilized as a negative control. U373 Cln6wt , U373 Cln6G123D and U373 Cln6M241T cells expressing shRNA-SEL1L or shRNA-GFP were treated with the proteasome inhibitor ZL 3 VS (10 μM) for up to 5 h. The total cell lysates were subjected to immunoblot analysis to determine the levels of Cln6 polypeptides ( Figure 5 ). Cln6 wt levels were not altered upon the inclusion of the proteasome inhibitor or expression of shRNAs (Figure 5, lanes 1-3 and 10-12) . As expected, in shRNA-GFPexpressing cells, the levels of Cln6 G123D and Cln6 M241T increased upon treatment with the proteasome inhibitor ( Figure 5 , lanes 4-6 and 7-9 respectively). Strikingly, significant levels of both Cln6 G123D and Cln6 M241T polypeptides were observed in SEL1L-knockdown cells ( Figure 5, lanes 13-18) . Since SEL1L was knocked down by only ∼50% (see Supplementary Figure S3 at http://www.bioscirep.org/bsr/029/bsr0290173add.htm), a greater attenuation of Cln6 G123D and Cln6 M241T degradation would probably be observed upon complete knockdown of SEL1L. The GAPDH immunoblot confirmed equal loading of the cell lysates ( Figure 5, lanes 20-38) . These results strongly support the hypothesis that Cln6 G123D and Cln6 M241T degradation is dependent on SEL1L and is regulated by ER quality control.
DISCUSSION
NCLs are neurodegenerative childhood diseases caused by mutations within nine different cln genes [31] . Cln mutants are either truncated versions of the protein or contain point mutations which yield enzymatically inactive polypeptides or molecules that never reach their final destination. The early processing events within the ER can dictate the fate of these mutant proteins. In fact, specific genetic diseases, including cystic fibrosis, emphysema, Fabri disease, Gaucher disease, G M1 gangliosidosis and Tay-Sachs disease are caused by mutations within proteins that are subjected to ER quality control [32, 33] . The present study shows for the first time that the Cln6 mutants Cln6 G123D and Cln6 M241T implicated in the onset of NCL type 6 are unstable and degraded in a proteasome-dependent manner. Hence the development of NCL may be attributed to the instability of the mutant polypeptide, implying that ER quality control contributes to the onset of disease.
ER quality control has evolved to prevent the egress of defective membrane or secretory polypeptides from the ER. In most cases, the misfolded proteins are recognized by ER chaperones such as BiP, calnexin, and PDI [34, 35] and extracted through the ER membrane via a proteinaceous channel to be degraded by the proteasome. The recruitment of the degradation substrate to the dislocon occurs through an interaction with membranebound Ubcs (ubiquitin-conjugating enzymes) (i.e. Ubc7, Ubc1 and Ubc6), E3 ubiquitin ligases [i.e. gp78, Hrd1/Der3, Doa10, HsHrd1 (human Hrd1), trc8 and TEB4] [27] , and factors, such as the Derlin family of proteins and SEL1L. Once at the site of dislocation, p97 complexed with Npl4 and Ufd1 extracts the ubiquitin-conjugated dislocated substrate through the membrane [29, 36] . The N-linked glycan attached to the polypeptide would then be removed efficiently, followed by deubiquitination and degradation by the proteasome. The mutant Cln6 proteins are (Figure 4) . Since the knockdown of SEL1L caused an increase in the levels of the Cln6 mutants, it is possible that SEL1L contributes to the instability of Cln6 G123D and Cln6
M241T
proteins. Collectively, these results are consistent with the theory that Cln6 G123D and Cln6 M241T mutant proteins are recognized and disposed of by the ER dislocation/degradation apparatus.
The Cln6 G123D and Cln6 M241T mutants are degraded with fast kinetics (Figure 1) . Given the fact that the Cln6 protein spans the membrane seven times, we would expect the degradation kinetics to be similar to the degradation kinetics of CFTR (cystic fibrosis transmembrane conductance regulator) mutants [37] . Why are these aberrant proteins degraded in such a fast manner? Since both Cln6 mutations lie within the transmembrane regions, the amino acid changes may disrupt the stability of the transmembrane domains and induce a drastically misfolded protein that is quickly discarded for degradation by the proteasome. The severity of the misfolded state of the protein can dictate directly the half-life of the polypeptide. Therefore Cln6 G123D would be in a more native state than Cln6 M241T . Nevertheless, the dramatic instability of the Cln6 mutants could prove to be a useful model system to study how multi-membrane spanning proteins are dislocated across the ER membrane.
The degradation of aberrant Cln6 polypeptides implies that those proteins are thwarted in their cellular function, which eventually leads to the accumulation of insoluble proteolipid material in the lysosomes. It remains to be clarified whether increasing the stability of these mutants would allow the Cln mutant to regain at least partial wt activity. Therefore proteasome inhibitors may be considered as potential therapeutics for NCL type 6 if the stabilized Cln6 mutant would retain at least partial activity. In fact, understanding the process of ER quality control in the development of specific genetic diseases has already yielded promising results in the treatment of Fabri disease caused by mutations in α-galactosidase polypeptides. Namely, 1-deoxygalactonojirimycin, a competitive inhibitor of α-galactosidase, could stabilize an α-galactosidase mutant protein and correct its trafficking defect [38] . In addition, chemical chaperones could rescue some lysosomal storage diseases caused by inherited mutations, such those mutations which cause Gaucher disease, G M1 gangliosidosis and Tay-Sachs disease [39] [40] [41] . The present study serves as a preliminary guide for identifying potential new treatments against NCL that could be examined in the animal models available. A number of spontaneous animal forms of NCL have been described in sheep, dogs and mice [42] [43] [44] . The mouse models of NCLs, Ppt1 −/− [45] , Ppt1 ex4 knockout [46] , Tpp1 neo ins R446H knockout [47] , Cln5 −/− knockout [48] , Cln6 nclf spontaneous mutant [49] , Cln8 mnd spontaneous mutant [50] , Cln3 −/− knockout [51] , Cln3 Δex7/8 knock-in [52] and Cln3 knockout [53] demonstrate phenotypes that closely resemble the major features of human NCLs. They all show clinically relevant behavioural and pathological changes that indicate a progressive neurodegenerative disorder. The value of animal models for neurodegenerative disorders lies largely in the utility of these models in evaluating potential therapeutic interventions in the future [54] Cln6 mutants associated with neuronal ceroid lipofuscinosis are degraded in a proteasome-dependent manner Kristina 
Figure S1 Higher-molecular-mass species of Cln6
G123D and Cln6
M241T accumulate upon treatment with a proteasome inhibitor (A) Cln6 polypeptides were recovered from U373 Cln6wt (lanes 1 and 2), U373 Cln6G123D (lanes 3 and 4) and U373 Cln6M241T (lanes 5 and 6) cells treated with (+) or without (−) the proteasome inhibitor ZL 3 VS. U373 cells were used as a negative control. The immunoprecipitates (lanes 1-7) and total cell lysates (lanes [8] [9] [10] [11] [12] [13] [14] from the respective cells were subjected to immunoblot analysis using an anti-HA antibody. (B) The total cell lysates from (A) were also subjected to an anti-ubiquitin antibody immunoblot analysis. The smear in lanes 2, 4 and 6 represents polyubiquitinated polypeptides. The Cln6 proteins and higher-molecular-mass Cln6 polypeptides (*) are indicated. Molecular masses are shown on the left-hand side. were subjected to subcellular fractionation [1] . The 100 000 g supernatant containing the cytosol (lanes 1-6 and 14-19), 100 000 g membrane fraction containing ER-derived microsomes (lanes 7-12 and 20-25) and U373 Cln6wt total cell lysates (TCL) were subjected to an immunoblot analysis using anti-HA (lanes 1-13) and anti-calnexin (lanes 14-26) antibodies. The presence of the ER membrane protein calnexin confirms the isolation of ER microsomes. The Cln6 proteins and calnexin are indicated. Molecular masses are indicated on the left-hand side.
Figure S3 Analysis of SEL1L-knockdown cells
Total cell lysates from U373 cells and U373 Cln6wt , U373 Cln6G123D and U373 Cln6M241T cells expressing shRNAs against GFP or SEL1L were subjected to immunoblot analysis using anti-SEL1L (lanes 1-7) and anti-GAPDH (lanes [8] [9] [10] [11] [12] [13] [14] antibodies. SEL1L and GAPDH are indicated. Molecular masses are indicated on the left-hand side.
